Patent Application: Sigmari Ligand for Pancreatic Cancer Treatment
Summary
The USPTO has published a patent application (US20260083725A1) for a Sigmari Ligand for the treatment of pancreatic cancer. The application details a method involving a Sig-1R ligand to inhibit tumor growth and metastasis, filed on August 9, 2023.
What changed
This document is a publication of a United States patent application, specifically US20260083725A1, filed on August 9, 2023. The application, titled 'SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER,' describes a method for treating pancreatic cancer using a Sig-1R ligand. The inventors claim that this ligand inhibits stromal-induced tumor growth and the metastatic process by modulating the dialog between stromal and cancer cell compartments.
As this is a patent application, it does not impose direct regulatory obligations or compliance deadlines on entities. However, it signals potential future intellectual property and market exclusivity for treatments targeting pancreatic cancer via Sig-1R ligands. Companies involved in oncology drug development, particularly those researching pancreatic cancer, should be aware of this filing for competitive intelligence and potential licensing opportunities.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
SIGMARI LIGAND FOR THE TREATMENT OF PANCREATIC CANCER
Application US20260083725A1 Kind: A1 Mar 26, 2026
Inventors
Olivier SORIANI, Mauro-Franck BORGESE, Raphaël RAPETTI MAUSS, Richard TOMASINI, Patricia MELNYK
Abstract
Here the inventors applied PDAC-derived CAF secretome on pancreatic cancer cells and evaluated Sig-1R implication in stromal cues integration by PCC from signaling transmission to biological outcomes, at the cellular and physiological level. They demonstrated that the loss of Sig-1R in epithelial cells inhibits stromal-induced tumor growth and metastatic process. Thus, the inventors demonstrate that Sig-1R is a key actor of the dialog between stromal and cancer cell compartments The present invention relates to method for the treatment of pancreatic cancer in a patient in need thereof comprising a therapeutically effective amount of a Sig-1R ligand.
CPC Classifications
A61K 31/4745 A61K 31/7105 A61K 45/06 A61P 35/00 G01N 33/5011
Filing Date
2023-08-09
Application No.
19111369
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.